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 Abstract 
The incidence of head and neck cancers (HNC) is on the rise. The common 
therapies used, are associated with long-term toxicities that hamper the 
quality of life of HNC patients. Novel therapeutic strategies are required to 
reduce these. As drug discovery is expensive, time consuming and unreliable, 
in this project we have considered drug repurposing. Paracetemol, zinc 
acetate and colchicine are used for pain relief, common cold lozenges and 
gout treatment, respectively. We initially assessed their efficacy on the 
proliferation of a HNC cell line, SCC040, using an Alamar blue colometric 
assay. Results indicate zinc acetate significantly inhibited proliferation (62.68 
± 3.75% reduction, p≤0.001) compared to vehicle control. Secondly cell cycle 
analysis was carried out using propidium iodide staining and flow cytometry 
analysis. Colchicine was found to be a potent G2/M cell cycle blocker 
(p≤0.001) compared to its untreated control. Finally the effect of the drugs on 
the migration of SCC040 cells was assessed using a wound-healing assay. 
Colchicine was found to significantly inhibit migration compared to its vehicle 
control (79.55 ± 4.02% reduction p≤0.001). These results suggest that zinc 
acetate and colchicine are potential candidates for less toxic therapies in HNC 
patients.  
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1. Introduction  
1.1 Head & Neck cancer (HNC) 
Cancer is defined as the uncontrolled division and proliferation of abnormal 
cells (National Cancer Institute, 2013), to produce a malignant tumour 
(Weinberg, 2013). Carcinogenesis, the transformation from normal cells to 
cancer cells, is a complex pathway, which is characterized by a group of 
genetic mutations (Osborne et al, 2004). These mutations change the normal 
function of cellular pathways, which control regulatory mechanisms such as 
growth; and this leads to the development of cancer (Osborne et al, 2004).  
 
HNCs are a group of related neoplasms (Hashibe et al, 2007), which are 
carcinomas of the upper aero-digestive tract (Dobrossy, 2005). Almost all are 
squamous cell carcinomas (Argiris et al, 2008), meaning that they arise from 
the mucosal surface (Rezende et al, 2010). There are over 30 affected areas, 
which fall into the HNC group (NHS, 2012). HNC is therefore a term that 
groups epithelial malignancies, which arise from the nasal cavity, oral cavity, 
pharynx, larynx and paranasal sinuses (Rezende et al, 2010).  
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Figure 1: Illustrates the regions in the HNC group affected by carcinomas 
(National Cancer Institute, 2013). 
 
Symptoms associated with HNCs vary according to the site, but can include 
sore throat, hoarseness, difficulty swallowing and dysphagia and upon 
examination patients present with an identifiable primary site with a palpable 
neck mass (Haddad & Shin, 2008). From this, HNCs can therefore impact 
basic daily functions such as speaking, swallowing and breathing and from 
this have physical and emotional effects on the patient (Hanna et al, 2013). 
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1.1.2 HNC epidemiology 
The incidence of HNCs is on the rise within the industrialized world (Schoder, 
2013). There are approximately 600,000 new cases per year and 300,000 
deaths per year occurring worldwide from HNCs (Hashibe et al, 2007). The 
World Health Organization estimates that the oral cavity was the most 
commonly affected site with 389,000 new cases yearly (Boyle & Levin, 2008).  
 
Figure 2: Demonstrates the population, incidence and mortality of HNCs 
around the world (Mehanna et al, 2010) 
 
The highest incidences of HNCs are specifically seen in France, Brazil, 
Australia, South Africa and the Indian subcontinent (Mehanna et al, 2010). 
The lower rates seen in the Eastern Mediterranean, Americas and Europe 
may be due to a decline in exposure to carcinogens for example smoking 
(Figure 2; Mehanna et al, 2010). Other risk factors may explain high rates in 
south East Asia, where tobacco chewing is prominent (Her, 2001). Secondly 
nasopharyngeal cancer is largely restricted to China, which is linked to dietary 
risk factors such as the consumption of salted and preserved foods (Her, 
2001). This includes salted fish, which contains the known risk factor N-nitro-
sodimethylamine (Her, 2001). 
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Tobacco and alcohol alone are accountable for at least 75% of diagnosed 
HNCs in Europe and USA (Hashibe et al, 2007). Non-smokers who have 3 
alcoholic beverages a day increase their risk of developing the disease by a 
factor of two. As well as first hand smoking, passive smokers are also at risk 
of developing the disease (Rezende et al, 2010). When studied, 1114 patients 
from 4 separate areas of the USA, who drank alcohol and smoked, were 
found to have increased their risk of the development of HNC by 35 fold (Blot, 
1998). Secondly the type of drink taken was a variable factor, where hard 
liquor was a higher risk factor than beer (Blot, 1998). Genetics may also add 
to this factor as polymorphisms that occur in genes that encode for the 
metabolism of alcohol and tobacco can be mutated which contributes to HNC 
development (Rezende et al, 2010).  
 
As well as tobacco and alcohol, human papillomavirus (HPV) plays a strong 
role as a causative agent in the development of HNC (Argiris et al, 2008). 
HPV is a family of over 100 virus types and is a viral infection that spreads 
through contact with infected skin, body fluids and mucous membranes 
(Keogh, 2013).  HPV 16 and 18 are the most significantly associated with the 
development of HNCs, whereas HPV 6 and 11 are less likely to be causative 
factors (Chen et al, 2008). There is a strong indication that oral HPV is likely 
to be sexually acquired (Goon et al, 2009). The risk factors of HPV related 
HNCs are similar to that of cervical cancers and include the number of sexual 
partners, practice of oral sex and history of genital warts (Syrjanen, 2010). It is 
also seen that 6+ sexual partners increases the risk from 1.25 to 1.54 for 
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men, and early age of first sexual intercourse increases the risk from 2.36 to 
5.05 (Heck et al, 2010). 
 
1.2 HNC management 
HNC has various management techniques, which have gradually evolved 
from surgery being the main option (Bonner et al, 2006). Combination therapy 
is now more emphasized such as surgery followed by radiation, which is 
highly successful in those patients with early stage cancer (Garden et al, 
2004). Secondly a combination of radiotherapy and chemotherapy is a 
standard of care for the treatment of more advanced squamous cell 
carcinoma of the head and neck and has demonstrated a better overall 5 year 
survival rate over radiotherapy alone (Riaz et al, 2013). 
 
Cisplatin is a chemotherapy agent and when used alone or in combination 
with other chemotherapy agents such as fluorouracil, which produces clear 
improvements in locoregional control and is associated with higher longer 
survival rates in 60-90% of patients (Forastiere, 2013). This however, is still 
not as effective as chemoradiation, which when studied in multiple phase III 
clinical trails showed better overall survival rates (Forastiere, 2013).  
 
A downfall to the use of chemotherapy is the associated toxicities. With 
cisplatin there is an increase of short-term adverse effects, such as tiredness, 
fatigue and nausea (Cancer Research UK, 2013). Treatment can therefore, 
be majorly hampered by the long term major toxicicties, and adds difficulty 
when trying to intensify the treatment (Merlano et al, 2010). Patients that have 
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other medical conditions or are unable to withstand the effects of 
chemotherapy need alternative therapies that produce long survival rates 
without adverse effects  (Merlano et al, 2010).  
 
EGFR is abnormally overexpressed in epithelial cancers including HNCs, and 
this high expression is associated with poor clinical outcome (Bonner et al, 
2006). In recent years the management of HNC has been advanced by the 
development of therapies using monoclonal antibodies (Kabolizadeh et al, 
2012). Cetuximab is directed against the epidermal growth factor receptor 
(EGFR) and shows clinical activity in HNC (Kabolizadeh et al, 2012). 
Cetuximab works by inhibiting the ligand-binding domain of EGFR and 
sensitizes cells to the effects of radiation (Bonner et al, 2006). When studied 
by Bonner et al (2006) it was found the there was prolonged survival in 
patients treated with cetuximab and radiotherapy over those treated with 
radiotherapy alone in advanced stage disease. This offers a less toxic option 
for therapy (Riaz et al 2013).  
 
HNCs have a huge impact on the quality of life of a patient and they often 
require long term care, which can place financial pressure on the institution 
providing the treatment (Hunter et al, 2005). This shows that it is highly 
necessary to develop advanced treatment methods to not only reduce 
mortality but to reduce complications from treatment by developing more 
targeted therapies such as monoclonal antibodies, which may be able to 
improve patient quality of life (Hunter et al, 2005).  
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1.3 Drug repurposing 
At present pharmaceutical drug discovery is a very expensive process with 
the cost of developing one therapeutic soaring as high as $2billion and taking 
10 – 15 years (Boguski et al, 2009). Another downfall to the current drug 
development programmes is that the number of new chemical and biological 
entities that are being approved by the Federal Drug Agency (FDA) has been 
declining since the late 1990’s (Boguski et al, 2009). However drugs that have 
already been approved by the FDA, are eligible for approval for a second 
purpose that it’s seen to be fit for (Boguski et al, 2009). This makes the 
process of drug development much quicker (Boguski et al, 2009).  
 
From this it is very apparent that there is a need for a different approach to 
drug discovery, which is where drug repurposing becomes of huge interest. 
Drug repurposing is the development of existing licensed drugs for new 
indications (Sleigh & Barton, 2010). Repurposing therefore requires finding 
novel therapeutic indications of drugs compared to the initial use, for which, 
they were designed and approved for (Oprea & Mestres, 2012).  
 
Repurposing programmes can make research and development less costly, 
more reliable and more predictable (Boguski et al, 2009). This predictability 
comes from existing clinical and pharmacokinetic data on drugs, which can be 
implemented into new repurposing, programmes and creates and accelerated 
route for drug discovery (Li & Jones, 2012).  
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Drug repurposing has already had a presence in the treatment of cancer, for 
example, the commonly used diabetes type II drug, Metformin (Gotlieb et al, 
2008). Metformin has been evaluated for its efficacy in ovarian cancer cell 
lines it has been found to induce dose and time dependent inhibition of growth 
(Gotlieb et al, 2008). Secondly in patients, metformin decreases cancer 
incidence (Sahra et al, 2010). Anti proliferative effects of metformin have been 
observed in cancers of the breast, ovary, glioma, prostate and colon, showing 
its wide variation in possible cancer therapies from a repurposing programme 
(Rattan et al, 2009).  
 
Another example of a repurposed drug is a sedative, called thalidomide, 
which was used for morning sickness in the late 1950’s, however patients who 
were taking the drug were found to have children born with severe birth 
defects and the drug was withdrawn from the market (Boguski et al, 2009). 
However at present the drug has been found to have a great use in leprosy 
and also showed anti-angiogenesis properties, which led to its use in the 
treatment of multiple myeloma (Shaughnessy, 2011).  
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Figure 3: Shows repurposed drugs, with their initial use and repurposed use 
(Shaughnessy, 2011) 
 
Repurposing of drugs is a multistep pathway that begins with the initial 
assessment of a potential drug candidate. Cell lines are screened to evaluate 
potential of possible drug targets, and these candidates can be taken forward 
for further investigation and clinical trials to validate and prove findings 
(Bogsuki et al, 2009). Repurposing programmes are a highly productive as 
although they involve vast amounts of specific research and clinical trials, the 
lessened cost and time taken to get a drug on the market compared to 
developing one from scratch, is of great interest.  (Padhy & Gupta, 2011). 
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1.4 Mechanisms and uses of the target drugs 
1.4.1 Colchicine 
Colchicine is an alkaloid, derived from a plant source known as Colchicium 
autumnale (Neil & Schermann, 2006). Colchicine possesses anti-inflammatory 
and anti-mitotic properties (Neil & Schermann, 2006). Its initial purpose is in 
gout and Mediterranean fever as well as more recently cystic fibrosis and 
cirrhosis (Neil & Schermann, 2006). Gout is a type of arthritis, where crystals 
of sodium urate forms inside of the joints (NHS, 2012a) and Mediterranean 
fever is an auto-inflammatory disorder, which causes unprovoked 
inflammation (Rolden et al 2008). Colchicine is used due to its anti 
inflammatory properties (Neil & Schermann, 2006). The precise mechanism of 
action of colchicine is unknown (Ly et al 2007). However it is thought to act by 
blocking the inflammatory response, which prevents uric acid crystal formation 
in gout (Ly et al 2007).  Secondly it is thought to act by inhibiting cellular 
pathways in the inflammatory response to stop the secretion of cytokines 
(involved in promotion of cell signaling) and chemokines (involved in 
promoting migration) (Neil & Schermann, 2006). 
 
Colchicine also possesses anti mitotic properties, which works by preventing 
tubulin incorporation into microtubules, which in turns prevents the elongation 
of microtubules and disrupts the mitotic spindle during cell division (Neil & 
Schermann, 2006). This halts cell division and induces cell cycle arrest 
leading to apoptosis of the cell (Zhou, 2005).  
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Microtubule drugs are important in cancer chemotherapy, as their specific 
ability to arrest the cell cycle and initiate programmed cell death in many 
tumour types can be highly beneficial, as it can inhibit aggressive tumour 
growth (Checchi et al, 2003). Microtubule targeting agents are already 
successfully being used clinically to treat cancers and open a huge interest in 
pursuing new options for therapy in other cancers as well as improving the 
efficacy and toxicity profiles of the existing drugs (Migralese & Carlson, 2006). 
 
This mechanism can therefore be used to target cancer cells and induce 
apoptosis, which in a previous study by Chen et al (2012) where in normal 
liver cells, colchicine was able to induce a loss of mitochondrial membrane 
potential, which is an early apoptosis event, which in turn activated caspase 3 
and cause apoptosis. This may explain other studies where colchicine has 
had a positive effect in treatment of breast, cervical, lung and gastric cancers 
(Chen et al, 2012).  
 
1.4.2 Zinc Acetate 
Zinc acetate is a salt of its pure form, zinc (NCBI, 2013) and its main use is in 
Wilson’s disease, which is an inherited disorder caused by the accumulation 
of copper in the brain/liver (NCBI, 2013). The accumulation of copped is toxic 
and in worst-case scenarios leads to liver failure (Wilsons Disease Support 
Group, 2012). Zinc acetate works by inducing metallothionein, which when 
bound to zinc, prevents the absorption of copper from the intestinal tract and 
endogenously secreted copper to reduce copper levels (EuroWilson, 2012).  
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Zinc acetate can also be found in lozenges for the common cold where it 
gives a reduction in nasal discharge and coughing (Fitzgerald & Bao, 2000), 
which is thought to be by inhibition of viral replication (such as the rhinovirus 
(Hulisz, 2004) by interfering with protein cleavage (Jackson et al, 2000).  
 
In studies carried out in prostate cancer, zinc acetate has shown to have a 
positive effect on tumour volume in mice, however the results obtained in 
human studies are highly inconsistent (Gonzales et al, 2009). 
 
 
Figure 4: Black Line: Saline Control, Grey Line: 3mM zinc acetate. Figure 
showing a study carried out on mice for prostate cancer, where there is a 
reduction in tumour volume (mm3) over the 20-day period with zinc acetate, 
compared to the saline control (Gonzales et al, 2009). 
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Zinc in the extracellular environment of cells is highly important in the 
transformation of healthy to malignant cells. In normal cells it is broken down 
to Zn2+ molecules and it enters epithelial cells via ZIP transporters where it 
inhibits m-acotinase and prevents oxidation of citrate in the Krebs cycle. 
Secondly Zn2+ induces Bax to form pores in the outer mitochondrial 
membrane to allow cytochrome c to move through and interact with caspases 
to cause apoptosis. However in malignant cells, there is a reduced influx of 
Zn2+ and a lower intracellular zinc content and citrate is oxidized in the Krebs 
cycle. Without this Bax is unable to form pores to allow cytochrome c to enter, 
so the pro-apoptotic effect of zinc is abolished leading to energy efficient 
proliferating cells (Franz et al, 2013). This mechanism is shown in Figure 5. 
This gives a strong understanding of the importance of zinc and its pro-
apoptotic effect in healthy cells.   
 
Figure 5: Zinc acetates role in the transformation from healthy cells to 
malignant cancer cells (Franz et al, 2013)  
 
 14 
This mechanism highlights the importance of zinc in the extracellular 
environment. Zinc homeostasis is an important factor as zinc is essential for 
cell proliferation, differentiation and the regulation of mitosis and DNA 
synthesis (Bayersmann & Haase, 2001). Secondly, it is a structural 
component of many proteins including proteins involved in cellular signaling 
pathways and transcription factors, it is essential to maintain zinc levels 
correctly for the healthy function of a cell (Bayersmann & Haase, 2001).  
 
Zinc is able to modulate cellular signal recognition and can stimulate/inhibit 
activity of transcription factors, which shows the importance of zinc in the 
healthy function of a cell (Bayersmann & Haase, 2001). The homeostatis of 
zinc and its ability to regulate cell function is potentially behind the mechanism 
of action behind zinc acetate as a potential cancer therapy agent. This is 
because, a disruption in the regulation of zinc may lead to the inability of the 
cell to function correctly, so increasing the uptake of zinc, may cause induced 
cell death.  
 
1.4.3 Paracetemol 
Paracetemol, also known as acetaminophen is one of the most popular and 
widely used drugs for treating pain and fever (Prescott et al, 2000). 
Paracetemol has been used clinically for over a century (Clissold et al, 1986) 
and has a clearly established role as an analgesic for mild or moderate pain 
(Prescott et al, 2000). Following administration it is absorbed from the 
gastrointestinal tract and distributes evenly throughout most tissues and fluid 
(Forrest et al, 1982). The action of paracetemol at a molecular level is not 
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clear (Graham & Scott, 2005) but is generally considered as a weak inhibitor 
of prostaglandin production leading to its analgesic properties (Clissold et al, 
1986).   
 
In therapeutic doses paracetemol is seen as a safe drug that produces fewer 
side effects than a drug such as aspirin (Clissold et al, 1986). However one of 
the main concerns associated with it is that in overdose it can cause severe 
hepatic necrosis (Forrest et al, 1982) or hepatotoxicity (Cllssold et al, 1986). 
This however only occurs when doses over 10g-15g are taken (Clissold et al, 
1986).  
 
In terms of cancer, paracetemol is commonly used to alleviate pain as it 
causes minimal added side effects (Stockler et al, 2004). However there is 
some concern with the carcinogenic potential of paracetemol due to it being 
the major metabolite of phencacetin, which has been identified as a human 
carcinogen by the International Agency for Research on Cancer and due to 
this was withdrawn from the market in many countries (Friis et al, 2002). Due 
to this link between malignant tumours, mainly of the urinary tract, and 
phenacetin, paracetemol studies have also focused on these cancers (Friis et 
al, 2002). Results for paracetemol in urinary tract cancer have been 
inconsistent (Friis et al, 2002). However any increase or decrease in cancer 
risk from the drug, due to its widespread use, would have huge public health 
implications and therefore is worth characterizing further (Friis et al, 2002).  
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Paracetemols use in cancer therapy is fairly uncharacterized and doesn’t 
have a link into how the drug may possibly interplay in cancer therapeutics. 
This is a further reason to characterize and understand the mechanism, if any, 
that paracetemol has on cancer cells lines/primary cells.  
 
1.5 Aims and Objectives 
The aims of this project are 3 fold. Firstly I will screen zinc acetate, colchicine 
and paracetemol to determine if they have an anti-proliferative effect in head 
and neck cancer cell lines. Secondly I will explore and confirm their 
mechanisms of action using scratch wound assays and cell cycle analysis 
using flow cytometry. The results from these experiments should enable us to 
determine whether these drugs are useful as possible targets in repurposing 
programmes for head and neck cancer treatments.  
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2. Materials & Methods 
2.1 Cell Lines 
SCC040 (UPCI-SCC-040, DMSZ Serial #ACC660) oral squamous cell 
carcinoma cell lines were brought from the Leibniz institute DMSZ; a German 
Collection of Microorganisms and cell cultures. SCC040 is a HPV negative 
cell line established from an oral squamous cell carcinoma of a 50-year-old 
Caucasian male.  
 
2.1.2 Maintenance of Cell Lines 
Cell lines were maintained at 37°C with 5% CO2 in Dulbecco’s modified 
eagles medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS) 
(Sigma #F75524), 2mM L-glutamine (Invitrogen #25030-123) and 1% 
penincillin/streptomycin (Invitrogen #15070-063). Cell lines were incubated in 
a 75cm3 flask. Cells were split 1:5 twice a week.  
 
2.1.3 Preparation of Cell Lines 
Media was removed from the flask and cells were washed with 5ml of 
Phosphate Buffer Saline (PBS). PBS was removed and 2ml of TrypLE™ 
express dissociation reagent (Life Technologies, Serial #12605-010) was 
added to the flask. Cells were incubated for 5-10minutes at 37°C and 5% 
CO2. 4ml of DMEM was added to the flask and cells were then transferred 
into a 15ml sterile tube, they were then spun down in a Starstedt LC24 
centrifuge (Serial #77759) for 4 minutes at 1100 RPM at room temperature to 
form a pellet. The media was removed and cell pellet was re-suspended in 
10ml of DMEM for use.  
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2.2 Drugs 
Colchicine (Serial #C258000), paracetemol (Serial #P0300000), zinc acetate 
(Serial #96459) and Staurosporine (Serial #S4400), were purchased from 
Sigma Aldrich. Cisplatin (Serial #1550) was purchased from Cambridge 
Bioscience.  
  
The three target drugs, colchicine, paracetemol and zinc acetate were firstly 
made as a stock solution. Stock solutions of the drugs were made using water 
for Colchicine and Zinc Acetate, and DMSO for Paracetemol, Staurosporine 
and cisplatin. Colchicine stock solution was made at a concentration of 
0.175mM, paracetemol was made at 1323mM and zinc acetate was made at 
1600mM. This stock solution was then stored at -4°C and thawed for use. 
These stocks were 10000x the working concentration for assays. The final 
concentration of drugs used in each assay was 1x. For colchicine this was 
0.0175µM, for paracetemol this was 132.3µM and for zinc acetate this was 
160µM. 
 
Staurosporine and cisplatin stocks were prepared using DMSO. 
Staurosporine stock concentration was 1600mM, and cisplatin was 10mM. To 
prepare stocks for each assay the stock solution concentrations were diluted 
using DMEM.  
 
Cyclohexamide was brought from Sigma Aldrich (Serial #C4859).  
Cyclohexamide was ready diluted in DMSO at a stock concentration of 
100mg/ml.  
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2.3 Proliferation Assays 
Proliferation assays were carried out in 96 well plates. To count the cells, 10µl 
of the 10ml prepared suspension (See 2.1.3) were added 1:1 to 10µl of 
Trypan Blue stain (0.4%) (Life Technologies, Serial #T10282). 10µl of this 
was added to a Countess chamber slide (75 mm x 25 mm x 1.8 mm; depth: 
100µm) (Life Technologies, Serial #C10228). Cells were counted using an 
Invitrogen Countess®; automated cell counter (Serial #C10227). 
 
Cells were diluted to a concentration of 25,000 cells/mL and plated at 100µl 
per well to give a final concentration of 2500 cells per well. Cells were 
incubated for 24hours at 37°C with 5% CO2.  
 
Treatments were added at 2x concentration in 100µl media to give a final well 
volume of 200µl and a final concentration of 1x. Treatments were as follows; 
DMEM (Negative untreated control), DMSO (vehicle control for 
Paracetemol/Cisplatin), Water (Vehicle control for zinc acetate and 
colchicine), Zinc Acetate (160µM), Colchicine (0.0175µM), Paracetemol 
(132.3µM), Cisplatin (5µM), Cisplatin (10µM) and Cisplatin (15µM). 
 
As a negative control, media only plates were prepared to mimic the cells 
plate for each time point. For this 100µl of media was treated with 100µl of 
each of the treatments. This value would be deducted from final fluorescence 
readings to eliminate the effects the drugs may have on auto fluorescence.  
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Separate plates were made for each time point (1x media plate and 1x cell 
plate) for each of the three time points (24hours, 48 hours, 72 hours).  
 
To measure proliferation Alamar Blue cell viability reagent (Life Technologies, 
Serial #DAL1025) was added 1:10 (20µl per well) 4 hours before the time 
point (20hr for 24hr time point, 44hour for 48hour time point and 68hour for 
72hour time point) and incubated with the reagent at 37°C with 5% CO2.  
 
Plates were de-lidded and read using a Wallac Victor2 1420 (Serial #1420-
832) multi label counter plate reader for fluorescence at 550/590nm. 
 
The assay was repeated three times, and within each assay cells were 
treated in triplicate. An average of the triplicate technical repeat readings and 
an average from the ‘no cells’ plate were taken. The average of the no cells 
plate was deducted from the cells plate for each treatment. These values 
were converted to percentages of the untreated control at the same point.  
 
2.4 Migration Assay 
From the 10ml suspension (prepared in 2.1.3), cells were counted and diluted 
to 100,000 cells per ml using DMEM. 2mL of cells were plated in a 12 well 
assay plate (200,000 cells per well). Cells were incubated for 24hours at 37°C 
and 5% CO2 until a confluent monolayer was formed. Media was removed 
and 1ml of fresh DMEM was added to each well. 
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Treatments were added at 2x concentration in 1ml media to give a final well 
volume of 2ml and a final concentration of 1x. Treatments were as follows: 
DMEM (Negative untreated control), DMSO (vehicle control for 
Paracetemol/Cisplatin), Water (Vehicle control for zinc acetate and 
colchicine), Zinc Acetate (160µM), Colchicine (0.0175µM), Paracetemol 
(132.3µM), Cisplatin (15µM), Staurosporine (2µM), Staurosporine (4µM), 
Cyclohexamide (3µM) and Cyclohexamide (5µM).  
 
After 24hours of drug treatment, a scratch wound was created using a pipette 
tip to scratch through the cell monolayer vertically. Cells were imaged at 
0hour and 24hour using a Nikon Eclipse TS100 microscope at 10x 
magnification and a bright field light. Images were captured using Q-capture 
image software. 3 images for each treatment were taken. 
 
The assay was repeated three times, and within each assay cells were 
imaged in triplicate. The area of the scratch wound was calculated using FIJI 
is just image J image processing package and an average of the triplicate 
images was calculated. This was compared to the area at 0hr to calculate the 
percentage closure from 0hours to 24hours in each treatment type. Readings 
were calculated as percentage closure compared to the untreated control. 
 
2.5 Flow Cytometry; Cell cycle analysis 
From the 10ml suspension (prepared in 2.1.3), cells were counted and diluted 
to 50,000 cells per ml using DMEM. 2ml of this was then plated into a 6 well 
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assay plate, and cells were incubated at 37°C and 5% CO2 to settle and 
adhere for 24 hours.  
 
Cells were then treated (3 wells per treatment) 1:1 in triplicate with 1ml of the 
following treatments: DMEM (Negative untreated control), DMSO (vehicle 
control for Paracetemol/Cisplatin), Water (Vehicle control for zinc acetate and 
colchicine), Zinc Acetate (160µM), Colchicine (0.0175µM), Paracetemol 
(132.3µM) and Cisplatin 15µM.  
 
Cells were then incubated for 16hours or 48hours at 37°C and 5% CO2. 
 
Media from each triplicate well for each treatment was removed and stored in 
a 15ml falcon tube. Cells were then washed twice in 1ml of cold PBS to 
prevent cells clumping. PBS was removed and 500µl of TrypLE™ express 
dissociation reagent was added to the well and were incubated for 5-
10minutes at 37°C and 5% CO2. Triplicate wells for each treatment containing 
500µl TrypLE™ were combined in this step and added to the previously 
removed media for each specific treatment.  
 
Cells were then spun down in a Starstedt LC24 centrifuge (Serial #77759) for 
4 minutes at 1100 RPM at room temperature to form a pellet. Media was 
removed from the falcon tube and the pellet was re-suspended in 500µl of cell 
cycle buffer (10µg/ml propidium iodide, 10-4 M sodium chloride and 1% triton 
x100 in distilled water). Samples were transferred into FACS tubes (BD 
Falcon™ 5ml Polystyrene Round-Bottom Tubes 12x75mm, Serial #352052) 
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and stored at 4°C and protected from the light. Samples were analyzed by 
flow cytometry using the Becton Dickinson FACS Calibur machine and Becton 
Dickinson Cell Quest software, after 1 hour.  
 
Samples were vortexed before running. Samples were run for 20,000 events 
and resulting histogram plots were not gated. S phase was calculated using 
the following calculation: 
  
S-phase = 100 – (G0/G1 x 2) + (G2/M x 2) + Sub-G1 + Doublets  
 
The assay was repeated three times and an average of the percentage of 
cells in each cell cycle phase was taken. 
 
2.6 Statistical Analysis of Results 
Triplicate results for the Alamar Blue assay and Migration assay were 
analyzed for statistical significance using a multiple comparisons One-Way 
ANOVA and post-analyzed using Dunnett’s multiple comparisons test, using 
the GraphPad Prism 6 software.  
 
Flow Cytometry data was analyzed using a paired one-way ANOVA, using the 
GraphPad Prism 6 software.   
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3. Results 
3.1 SCC040 Alamar Blue Proliferation Assay  
 
From figure 7; at 24 hours, from the statistical analysis, there is no significant 
difference between zinc acetate, colchicine, paracetemol and their vehicle 
controls (Zinc acetate and colchicine vehicle control is water, and paracetemol 
is DMSO).  By 48 hours, paracetemol and colchicine both show no significant 
difference from their vehicle only control, DMSO and water, respectively. Zinc 
acetate however, shows a 34.11 ± 8.98% decrease in proliferation compared 
to water (P≤0.05). Finally at 72 hours Zinc acetate also shows a strong 
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statistical difference compared to its vehicle only control, with a 62.68 ± 
3.75% decrease in proliferation compared to water (P≤0.001). This indicates 
that from 48 hours to 72 hours the anti-proliferative effect of zinc acetate has 
increased and is the only target drug to show a statistically significant 
prevention of proliferation, from the target panel. 
 
From Figure 8, at 24 hours, cisplatin 5µM and 10µM, both show no significant 
difference from their vehicle control, DMSO. This shows that the DMSO is 
acting on the cells to give their anti-proliferative effect, with the cisplatin 
having no effect on this at this time point. However cisplatin 15µM, shows a 
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significant difference from its vehicle control (39.10 ± 5.34% decrease in 
proliferation, P≤0.05). Indicating that cisplatin at this dose is having an anti-
proliferative effect on the cells. At 48 hours, Cisplatin 5µM shows no 
significant difference compared to its vehicle control DMSO. However cisplatin 
10µM and 15µM, both show significant differences in proliferation from DMSO 
((40.65 ± 4.68% decrease, P≤0.05) and (49.07 ± 10.56% decrease, P≤0.01) 
respectively). Finally at 72 hours, cisplatin 10µM and 15µM again showed a 
significant difference from their vehicle only control ((41.29 ± 14.74% fold 
decrease, P≤0.05) and (60.47 ± 3.69% decrease P≤0.01) respectively).  
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As seen in figure 9 at the 24-hour time point, there is a significant difference 
between the untreated and DMSO controls (34.32 ± 15.01% decrease, 
P≤0.05), as well as the untreated and water controls (46.86 ± 11.12% 
decrease, P≤0.01). This indicates that at this time point, the vehicle controls 
were affecting cell proliferation. At 48 hours, there is no significant difference 
between the untreated control and the vehicle only controls. This shows that 
at this time point the DMSO and water are having no effect on the cells, as 
there is no difference compared to the untreated control. These results 
suggest that the cells at 24 hours are highly sensitive to any treatment as the 
cells are seeded at a low density and therefore are subject to being affected 
by any changes in their environment, such as the addition of low 
concentrations of DMSO.   
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3.2 SCC040 Migration Assay 
 
From Figure 10 it is possible to see that there is no significant difference 
between the two negative controls (DMEM and DMSO). Staurosporine and 
Cyclohexamide were also used as positive controls and show fairly similar 
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results in terms of percentage closure after 24 hours. Statistical analysis 
shows, Staurosporine 2µM and 4µM and Cyclohexamide 3µM and 5µM are all 
significantly different from the untreated control. Staurosporine 2µM shows a 
54.42 ± 2.47% difference in wound closure (P≤0.001) and Staurosporine 4µM 
shows a 67.06 ± 8.4% difference in wound closure (P≤0.001) compared to 
the untreated control. Cyclohexamide 3µM shows a 58.11 ± 11.02% 
difference in wound closure (P≤0.01) and Cyclohexamide 5µM shows 65.87 
± 8.13% difference in wound closure (P≤0.001) compared to the untreated 
control. This shows the anti-migratory effect of these drugs on the SCC040 
cell line and validates the assay as functioning correctly.  
 
Paracetemol shows no significant difference in wound closure from the 
untreated and DMSO control, indicating that this drug has no effect on wound 
closure. Colchicine has a significant effect on wound closure compared to the 
untreated control at 24 hours (79.55 ± 4.02%, P≤0.001) This shows that 
colchicine inhibits the migration of SCC040 cells. 
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3.2.1 Migration Assay - Zinc Acetate Treatment 
 
Zinc acetate treatment was also carried out on SCC040 cells. These assays 
were performed in triplicate with triplicate images for each treatment in each 
experiment. The date for zinc acetate was not included because there was 
only one experiment where zinc acetate treated cells were able to be imaged 
in a wound shape, as in the other in the other experiments cells were dead as 
shown in Figure 8. This result therefore indicates that zinc acetate in most 
cases kills the cells by 24 hours, therefore its effect on migration cant be 
measured. 
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3.3 Cell Cycle Analysis Histograms via Flow Cytometry  
3.3.1. SCC040 - 48hours Post Treatment Cell Cycle Analysis  
 
From Figure 12 it is possible to see that in the treatments (colchicine, 
paracetemol, zinc acetate and cisplatin) that the cell cycle histogram plots are 
A 
B B 
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indicating that the cells are dead by this time point. Untreated and the vehicle 
controls, DMSO and water, all show a healthy cell cycle by 48hours.  
 
3.3.2  SCC040 – 16 hours post treatment cell cycle analysis 
 
A 
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From Figure 13 it is possible to see that there is a G2/M cell cycle block with 
the colchicine treatment at 16 hours (p≤0.001) compared to the untreated 
control Secondly paracetemol also shows 2 cell cycle shifts, at G0/G1 
(p≤0.05) and G2/M (P≤0.05) compared to the untreated control. Cisplatin 
displays a statistically significant difference in the Sub-G1 phase compared to 
the untreated control (p≤0.05), indicating that there are a larger proportion of 
cells that are dead in the cisplatin treatment that in the untreated control. 
Lastly, water shows a significant difference in the G0/G1 phase of the cell 
cycle against the untreated control (p≤0.01). When compared to the untreated 
control, the other phases of the different treatments showed a non-significant 
difference in cell counts, which leads to the results indicating that there are 
only significant differences in some specific phases of the cell cycle.  
 
 
 
 
 
 
 
 
 
 
 
 
 34 
4. Discussion 
4.1 Anti-proliferative effects of Zinc Acetate 
The results obtained for the Alamar blue proliferation assay bring forward a 
candidate with anti-proliferative effects in the SCC040 HNC cell line. Zinc has 
been previously characterized as an important factor in the regulation of 
cancer cell growth and proliferation by altering the extracellular environment 
(Lecane et al, 2005). For example, extracellular zinc when in abundance, both 
free or loosely bound can impact the cells metabolism, survival and growth 
due to various factors. These include, elevated levels of zinc inhibiting 
glycolysis, specifically via the glyceraldehyde phosphatedehydrogenase 
enzyme and also inhibition of the citric acid cycle via the a-ketoglutarate 
dehydrogenase complex, which all contribute to the healthy growth of cells 
(Lecane et al, 2005). This shows that, in the assay in this investigation, adding 
zinc acetate, may have increased the amount of zinc in the extracellular 
environments, which may inhibit these key pathways, that regulate cells 
normal growth and proliferation, leading to an anti-proliferative effect,  
 
Zinc has been identified as a weak activator of extracellular signal regulated 
kinases (ERKs), which plays a role in the inhibition of cell growth, which 
occurs through the regulation of genes for proteins involved in the cell cycle 
such as p21Cip/WAF1 , however this mechanism is poorly defined (Park et al, 
2002). From this the treatment with zinc used in this study may consequently 
lead to the activation or signal transduction of ERK pathways, which can in 
turn lead to an inhibited cell growth (Park et al, 2002). This supports the 
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findings in this study, where zinc may activate kinases to inhibit cell growth, as 
seen in the alamar blue assay.  
 
In a previous study, when prostate carcinoma cells (LNCaP/PC-3 cell lines) 
were exposed to zinc, it resulted in necrosis of the cells, and the monolayer 
normally formed by the cells became detached and the viability of the cells 
was lost after 4-8 hours (Iguchi et al, 1998). This was previously seen in the 
migration assay when cells were treated with zinc acetate, showing that zinc 
acetate may have the same effect on various cell lines, due to its mechanism 
being linked with inhibition of key pathways that are needed for a healthy cells 
growth.  
 
For many studies that have been carried out, they have looked at zinc alone, 
though zinc acetate is producing results similar to those found when only zinc 
was used. For example, when the effect of Zn2+ molecules was studied in vitro 
the proliferation of a mouse melanoma cell line was inhibited via the Zinc ions 
when used at 10-3M (Borovanksy et al 1985). This indicates that zinc may be 
broken down in the cell, to then bring forward its anti-proliferative effect.  
 
In the study by Iguchi et al (1998) when prostate cancer cell lines were treated 
with zinc, necrosis of the cells was seen, which was determined by double 
staining with fluorescein-isothiocyanate-labeled annexin V and ethidium 
bromide. This may explain the results obtained in the Cell Cycle analysis for 
zinc acetate, as necrosis differs from apoptosis, and is characterized by no 
DNA fragmentation and the formation of apoptotic bodies, the methodology 
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used in this study would not be able to identify this possibility. Therefore to 
look at the necrotic effects of zinc acetate other methods of flow Cytometry 
based work such as Annexin V staining could be carried out.  
 
4.2 Colchicine; an inhibitor of wound closure 
From the results obtained in the scratch wound migration assay, it was 
possible to see that colchicine inhibited the migration of SCC040 HNC cells. 
In the alamar blue assay, colchicine had a non-significant effect on 
proliferation. This indicates that colchicine is has a more directed impact on 
the migration of cells than an anti-proliferative effect.  
 
Colchicine is able to interact with tubulin and alter microtubule structure 
(Bhattacharyya et al, 2008). This is important because, microtubules are 
strongly implicated with the polarization of migrating cells, but specifically how 
they do this is unclear and their involvement remains to be controversial 
(Small et al, 2002). Past research has indicated a crucial role for microtubules 
in the maintenance and direction and migration of cells (Schliwa et al, 1999). 
Therefore altering the microtubule structure will have an effect on the cells 
ability to migrate.  
 
In order to migrate cells require an interplay between microtubules and the 
actin cytoskeleton, which creates a polarization of the microtubules, which 
allows the microtubules growth at the leading edge of the cell, and shortening 
at the rear, for cell motility (Storer & Salmon, 1999). Cell movement itself is 
therefore regulated by polarization of the cell, the actin cytoskeleton and 
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adhesion complexes (Small & Kaverina, 2003). If this is primary interplay is 
inhibited, such as by colchicine, polarization of the cell cant take place, and in 
turn, motility is inhibited.  
 
Colchicine is known to alter the structure of microtubules and therefore 
provides an understanding of its mechanism of action in the migration study 
carried out. In line with this in a study carried out by Ganguly et al (2013), on 
cells using a vinblastine, which also alters the function of microtubules, they 
found that there was little cell movement and cells were non directional. 
These studies suggest that suppressing microtubule function, destabilizes the 
leading edge of migrating cells and also the is interference with the tail 
retraction of the cell, and this destroys motility (Ganguly et al, 2013). In the 
same way as vinblastine, colchicine may therefore be altering the necessary 
microtubule network needed for migration as seen in this study’s results.  
 
Secondly, microtubule dynamics that are suppressed by drugs may affect 
locomotion as well as make the direction of movement more random. In a 
study by Ganguly et al (2012) under conditions where altered microtubule 
function was found cells along the edge of the wound in a scratch wound 
assay still elongated toward the wound, however the process was inhibited by 
their inability to retract the tail end, leading to a different directional 
movement, or no movement. This supports the results from the scratch wound 
assay carried out in this study, where the wound closure was inhibited, but 
this study also shows there is a possibility that colchicine alters directed 
movement and cells may have been migrating, but possibly away from the 
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wound. To evaluate this in this study, further research would need to be 
carried out using live cell imaging in order to study the movement and 
direction of the cells.  
 
4.3 Colchicine cell cycle block 
From the flow Cytometry data, it was possible to see that colchicine induced a 
potent G2/M block. Compounds that interfere with microtubules, such as 
colchicine, have already been implicated as chemotherapeutic agents from 
the treatment of cancer (Zhou & Ginannakakou, 2005). As seen in the results 
from this study, colchicine’s interference with microtubule formation, results in 
spindle checkpoint arrest, leading to apoptotic cell death (Zhou & 
Ginannakakou, 2005). Microtubules are essential for mitosis, and colchicine is 
targets this in order to inhibit cell proliferation by blocking mitosis (Jordan & 
Wilson, 1998). However this result was not significantly seen in the 
proliferation assay from this study, though there is a decrease in cell 
proliferation seen in Figure 7. 
 
In a supporting study by Blajeski et al (2002), when breast cancer cell lines 
were treated with 100nM colchicine, seven of the ten cell lines arrested in 
mitosis due to microtubule disruption and triggering of the mitotic checkpoint. 
This shows that in other cancers the same effect is being seen from colchicine 
treatment.  
 
Colchicine interacts with tubulin and alters microtubule dynamics and this give 
a strong point of interest in HNC therapy, as although its use is limited due to 
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high toxicity in other therapies (Bhattacharyya et al, 2008), the results of this 
study give a possibility explore further, as its cell cycle blocking properties are 
now shown in HNC cell lines. This concept can therefore be taken forward 
and developed as a new treatment strategy that may be a more effective 
therapy option for HNC patients in the future (Zhou, & Ginannakakou, 2005). 
 
4.4 Assay results combined findings 
From the results gathered in this experiment, it was possible to see that zinc 
acetate was shown as an anti-proliferative drug and colchicine shown to hold 
anti-migratory properties. However in the proliferation assay, colchicine didn’t 
show a statistically significant difference in proliferation, but in the cell cycle 
colchicine blocked the cell cycle in the G2/M phase at 16 hours and induced 
death in a large proportion of cells by 48 hours. However as seen in Figure 10 
there is a proportion of cells not seen on the left hand side of the histogram, 
therefore showing all cells are not dead and these cells have been analyzed 
in the proliferation assay and shown to proliferate over the 72 hours. In the 
same way, zinc acetate and paracetemol were mostly dead by 48 hours 
however a proportion of the cells in the histogram are in the living and 
therefore are able to proliferate as seen in the proliferation assay.   
 
4.5 Further Research 
The experiments conducted, looking into the anti-proliferative and anti 
migratory effects of the three target drugs, colchicine, zinc acetate and 
paracetemol could be expanded in further research. The results found 
regarding the anti-migratory effects of colchicine can be further developed 
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through determining the divide between the anti-proliferative effects of the 
drugs and anti-migratory effects. As the drugs are all shown to produce anti-
proliferative effects in the HNSCC cell lines, a further expansion would be to 
use BrdU staining which is a marker for proliferating cells, that can identify 
cells proliferating from those that are migrating. Further to this analysis of 
invasion using Boyden Chamber invasion assays , which allow the movement 
of cells from one chamber into another can be used to determine is colchicine 
inhibits invasion secondary to migration.  
 
Secondly the expansion of work in to the mechanism of action behind the 
targets can be taken further. Though the understanding of colchicine’s 
mechanism of action has been partially determined, the use of flow cytometry 
using Annexin V and TUNEL could also be used to establish if the drugs are 
activating apoptosis. Alternatively the use of western blots could be carried 
out to determine if pro-apoptotic proteins are present such as caspases when 
treated with the target drugs. These further studies could then give a more all 
rounded understanding of the mechanisms that these drugs are producing an 
anti-proliferative effect via, as shown in the Alamar blue assay completed in 
this study. 
 
Lastly the use of a control cell line, from another type of cancer, could be used 
in order to determine and confirm the specificity of these candidate drugs to 
head and neck cancer. Secondly additional cell lines could be used such as 
those that are HPV- and HPV+ or P53-/P53+ as these risk factors represent 
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separate HNC groups, so could be analyzed to see if results differ between 
groups or if response rates are better or worse.  
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5. Conclusion 
In conclusion, from this study it has been possible to see that zinc acetate 
significantly inhibited proliferation of HNC SCC040 cells. Secondly through 
scratch wound healing assays, colchicine was identified as a potent inhibitors 
of migration. Cell cycle analysis using propidium iodide stain and flow 
cytometry indicated that colchicine blocked the cell cycle at G2/M phase 
which helped to further understand its mechanism of action in HNSCC cell 
lines. The results indicate that colchicine is a anti-migratory drug and G2/M 
block, whereas zinc acetate is an anti-proliferative drug. This has categorized 
these candidates into different sub sets subset of possible future therapy 
mechanisms. The research carried out in this study begins to explain the 
possibilities of the mechanisms of action behind the drug-repurposing 
candidates but has much room for expansion. However from this a basis of 
understanding of the mechanisms of action behind these candidates has been 
characterized. Further research can be carried out to investigate the 
mechanisms of action drugs have on other HNC cell lines or primary cells 
using other techniques such as BrdU staining or Annexin V staining and flow 
Cytometry. This would expand on this study and take a step forward in the 
drug-repurposing programme dedicated to these drugs, to understand their 
clinical relevance to a greater extent.  
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